This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study

Juan Carlos Pascual, MD; Joaquim Soler, PsyD; Dolors Puigdemont, MD; Rosario Pérez-Egea, MD; Thais Tiana, PsyD; Enrique Alvarez, MD, PhD; and Ví­ctor Pérez, MD, PhD

Published: March 18, 2008

Article Abstract

Objective: The aim of this double-blind, placebo-controlled study was to evaluate the efficacy and tolerability of ziprasidone in the treatment of adult patients with borderline personality disorder.

Method: Sixty DSM-IV borderline personality disorder patients were included from March 2004 to April 2006 in a 12-week, single-center, double-blind, placebo-controlled study. The subjects were randomly assigned to ziprasidone or placebo in a 1:1 ratio following a 2-week baseline period. The Clinical Global Impressions scale for use in borderline personality disorder patients (CGI-BPD) was the primary outcome measure, and other scales and self-reports related to affect, behavior, psychosis, general psychopathology domains, and clinical safety were included.

Results: Analysis of variance indicated no statistically significant differences between ziprasidone and placebo in the CGI-BPD. Nor were significant differences observed between groups in depressive, anxiety, psychotic, or impulsive symptoms. The mean daily dose of ziprasidone was 84.1 mg/day (SD = 54.8; range, 40-200). The drug was seen to be safe, and no serious adverse effects were observed.

Conclusion: This trial failed to show a significant effect of ziprasidone in patients with borderline personality disorder.

Trial Registration: clinical Identifier: NCT00635921

Volume: 69

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF